Recursion secures FDA agreement on Phase 3 design for REC‑4881 in FAP

Recursion Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed to the design of a registrational Phase 3 trial for its oral MEK1/2 inhibitor REC‑4881, intended to treat familial adenomatous polyposis. The randomized, double‑blind, placebo‑controlled study will enroll about 200 adults who have had colectomy or proctocolectomy and will use a composite event‑free survival primary endpoint. The trial is slated to begin in the second half of 2027 and the drug holds orphan‑drug and fast‑track designations.

The FDA alignment reduces regulatory uncertainty for REC‑4881, which could accelerate the path to market and support the recent rise in RXRX shares. The company’s AI‑driven platform may also benefit from the milestone, potentially enhancing its valuation.

  • 1Recursion reached agreement with the FDA on the Phase 3 trial design for REC‑4881.
  • 2The trial will enroll approximately 200 adults with FAP who have undergone colectomy or proctocolectomy.
  • 3REC‑4881 will be tested at a 4 mg dose.
  • 4The primary endpoint is a composite event‑free survival measure that includes removal of adenomas ≥10 mm, qualifying surgery, high‑grade dysplasia or cancer, or death.
  • 5The trial is scheduled to start in the second half of 2027.
  • 6REC‑4881 has received FDA Orphan Drug and Fast Track designations for FAP.
  • Material 5 states Phase 3 testing is expected to begin in the latter half of 2024, conflicting with the 2027 start date reported in materials 1‑4.

Sources